RZLT · NASDAQ · Biotechnology

Rezolute

Developing ersodetug for hypoglycemia caused by congenital and tumor hyperinsulinism.

$4.65
After-hours close+0.03 (+0.65%)
At close$4.62(−7.23%)
DateEstimateReportedSurprise
Sep 2026−$0.13
May 2026−$0.14−$0.16−15.5%
Feb 2026−$0.16−$0.22−37.5%
Nov 2025−$0.27−$0.18+33.3%
Sep 2025−$0.23−$0.26−13.0%

The latest year is open to everyone — the 41 quarters behind it read with an account.

Sign in
May 2025
Feb 2025
Nov 2024
Sep 2024
May 2024
Feb 2024
Nov 2023
Sep 2023
May 2023
Feb 2023
Nov 2022
Sep 2022
May 2022
Feb 2022
Nov 2021
Sep 2021
May 2021
Feb 2021
Nov 2020
Oct 2020
May 2020
Feb 2020
Nov 2019
Sep 2019
May 2019
Feb 2019
Dec 2018
Dec 2018
May 2018
Feb 2018
Nov 2017
Sep 2017
May 2017
Feb 2017
Nov 2016
Sep 2016
May 2016
Feb 2016
Nov 2015
Sep 2015
May 2015
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Sep 16, 2026−$0.13
May 12, 2026−$0.14−$0.16−15.5%
Feb 12, 2026−$0.16−$0.22−37.5%
Nov 6, 2025−$0.27−$0.18+33.3%
Sep 17, 2025−$0.23−$0.26−13.0%

The latest year is open to everyone — the 41 quarters behind it read with an account.

Sign in
May 13, 2025
Feb 12, 2025
Nov 7, 2024
Sep 19, 2024
May 15, 2024
Feb 13, 2024
Nov 13, 2023
Sep 14, 2023
May 11, 2023
Feb 10, 2023
Nov 9, 2022
Sep 15, 2022
May 12, 2022
Feb 9, 2022
Nov 12, 2021
Sep 15, 2021
May 17, 2021
Feb 10, 2021
Nov 12, 2020
Oct 13, 2020
May 14, 2020
Feb 12, 2020
Nov 14, 2019
Sep 10, 2019
May 10, 2019
Feb 14, 2019
Dec 31, 2018
Dec 14, 2018
May 15, 2018
Feb 14, 2018
Nov 14, 2017
Sep 22, 2017
May 15, 2017
Feb 2, 2017
Nov 14, 2016
Sep 28, 2016
May 16, 2016
Feb 16, 2016
Nov 16, 2015
Sep 30, 2015
May 15, 2015